TherapeuticsMD, Inc. (TXMD) P/E Ratio History
Historical price-to-earnings valuation from 2007 to 2025
Loading P/E history...
TXMD Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, TherapeuticsMD, Inc. (TXMD) trades at a price-to-earnings ratio of -10.6x, with a stock price of $2.01 and trailing twelve-month earnings per share of $0.03.
The current P/E is 198% below its 5-year average of 10.8x. Over the past five years, TXMD's P/E has ranged from a low of 0.7x to a high of 47.0x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, TXMD trades at a 147% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, TXMD trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our TXMD DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
TXMD P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $2B | 29.5 | 4.40 | +14% | |
| $2B | 25.3 | - | +419%Best | |
| $358B | 85.5 | - | -1% | |
| $151B | 19.5Lowest | - | -4% | |
| $42B | 30.0 | - | +183% | |
| $92B | 29.2 | 0.75Best | +15% | |
| $44B | 28.7 | - | +87% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
TXMD Historical P/E Data (2007–2025)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q3 | $1.08 | $0.02 | 47.0x | +334% | |
| FY2023 Q1 | Fri Mar 31 2023 00:00:00 GM | $3.75 | $5.34 | 0.7x | -94% |
| FY2008 Q1 | Mon Mar 31 2008 00:00:00 GM | $850.00 | $371.82 | 2.3x | -79% |
| FY2007 Q4 | Mon Dec 31 2007 00:00:00 GM | $1683.33 | $493.91 | 3.4x | -68% |
| FY2007 Q3 | Sun Sep 30 2007 00:00:00 GM | $2750.00 | $501.55 | 5.5x | -49% |
| FY2007 Q2 | Sat Jun 30 2007 00:00:00 GM | $4166.67 | $687.06 | 6.1x | -44% |
Average P/E for displayed period: 10.8x
See TXMD's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs TXMD Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare TXMD vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonTXMD — Frequently Asked Questions
Quick answers to the most common questions about buying TXMD stock.
Is TXMD stock overvalued or undervalued?
TXMD trades at -10.6x P/E, below its 5-year average of 10.8x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does TXMD's valuation compare to peers?
TherapeuticsMD, Inc. P/E of -10.6x compares to sector median of 22.3x. The discount suggests lower growth expectations or higher risk.
What is TXMD's PEG ratio?
TXMD PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2007-2025.